行情

TRIL

TRIL

Trillium治疗
NASDAQ

实时行情|Nasdaq Last Sale

0.3872
+0.0172
+4.65%
已收盘, 16:00 09/16 EDT
开盘
0.3696
昨收
0.3700
最高
0.3924
最低
0.3696
成交量
17.11万
成交额
--
52周最高
6.50
52周最低
0.2440
市值
1,418.53万
市盈率(TTM)
-0.2103
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TRIL 新闻

  • 本周开庭!苹果拟对抗欧盟140亿美元天价税单
  • 新浪科技.13小时前
  • 沪指震荡微跌 沙特石油设施遇袭、油价一度跳升20%
  • 新浪财经.13小时前
  • 沙特阿美据称仍在推进IPO工作 尽管设施受到重创
  • 新浪财经综合.13小时前
  • 若沙特局势恶化 韩国将考虑释放战略石油储备
  • 新浪财经综合.13小时前

更多

所属板块

生物技术和医学研究
+0.91%
制药与医学研究
-0.17%

热门股票

名称
价格
涨跌幅

TRIL 简况

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
展开

Webull提供Trillium Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。